These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 31573659)

  • 21. Use of cannabinoids for the treatment of patients with post-traumatic stress disorder.
    Forsythe ML; Boileau AJ
    J Basic Clin Physiol Pharmacol; 2021 Mar; 33(2):121-132. PubMed ID: 33662194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cannabinoids and the endocannabinoid system in anxiety, depression, and dysregulation of emotion in humans.
    Chadwick VL; Rohleder C; Koethe D; Leweke FM
    Curr Opin Psychiatry; 2020 Jan; 33(1):20-42. PubMed ID: 31714262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Effects of Cannabidiol, a Non-Intoxicating Compound of Cannabis, on the Cardiovascular System in Health and Disease.
    Kicman A; Toczek M
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Could Cannabidiol Be a Treatment for Coronavirus Disease-19-Related Anxiety Disorders?
    O'Sullivan SE; Stevenson CW; Laviolette SR
    Cannabis Cannabinoid Res; 2021; 6(1):7-18. PubMed ID: 33614948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of prior foot shock stress and Δ
    Rock EM; Limebeer CL; Petrie GN; Williams LA; Mechoulam R; Parker LA
    Psychopharmacology (Berl); 2017 Jul; 234(14):2207-2217. PubMed ID: 28424834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cannabis, Cannabinoids, and Sleep: a Review of the Literature.
    Babson KA; Sottile J; Morabito D
    Curr Psychiatry Rep; 2017 Apr; 19(4):23. PubMed ID: 28349316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cannabidiol Exerts Sedative and Hypnotic Effects in Normal and Insomnia Model Mice Through Activation of 5-HT
    Liu YM; Li JC; Gu YF; Qiu RH; Huang JY; Xue R; Li S; Zhang Y; Zhang K; Zhang YZ
    Neurochem Res; 2024 May; 49(5):1150-1165. PubMed ID: 38296858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cannabidiol (CBD) use in psychiatric disorders: A systematic review.
    Bonaccorso S; Ricciardi A; Zangani C; Chiappini S; Schifano F
    Neurotoxicology; 2019 Sep; 74():282-298. PubMed ID: 31412258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomised controlled trial of vaporised Δ
    Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cannabidiol and its Potential Evidence-Based Psychiatric Benefits - A Critical Review.
    Dammann I; Rohleder C; Leweke FM
    Pharmacopsychiatry; 2024 May; 57(3):115-132. PubMed ID: 38267003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of cannabis, cannabidiol and synthetic cannabinoid use with mental health in UK adolescents.
    Hotham J; Cannings-John R; Moore L; Hawkins J; Bonell C; Hickman M; Zammit S; Hines LA; Adara L; Townson J; White J
    Br J Psychiatry; 2023 Oct; 223(4):478-484. PubMed ID: 37485911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cannabis for psychiatric disorders - Has The Pendulum Swung Too Far?
    Alawadi S; Naguy A
    Asian J Psychiatr; 2022 Mar; 69():102995. PubMed ID: 34974321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD): A Systematic Review.
    Orsolini L; Chiappini S; Volpe U; Berardis D; Latini R; Papanti GD; Corkery AJM
    Medicina (Kaunas); 2019 Aug; 55(9):. PubMed ID: 31450833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic review of the antipsychotic properties of cannabidiol in humans.
    Iseger TA; Bossong MG
    Schizophr Res; 2015 Mar; 162(1-3):153-61. PubMed ID: 25667194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cannabinoids and the Microbiota-Gut-Brain Axis: Emerging Effects of Cannabidiol and Potential Applications to Alcohol Use Disorders.
    Karoly HC; Mueller RL; Bidwell LC; Hutchison KE
    Alcohol Clin Exp Res; 2020 Feb; 44(2):340-353. PubMed ID: 31803950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings.
    Elsaid S; Kloiber S; Le Foll B
    Prog Mol Biol Transl Sci; 2019; 167():25-75. PubMed ID: 31601406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medical use of cannabis. Cannabidiol: a new light for schizophrenia?
    Deiana S
    Drug Test Anal; 2013 Jan; 5(1):46-51. PubMed ID: 23109356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law.
    Mead A
    Epilepsy Behav; 2017 May; 70(Pt B):288-291. PubMed ID: 28169144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia.
    Levin R; Almeida V; Peres FF; Calzavara MB; da Silva ND; Suiama MA; Niigaki ST; Zuardi AW; Hallak JE; Crippa JA; Abílio VC
    Curr Pharm Des; 2012; 18(32):4960-5. PubMed ID: 22716146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment.
    Premoli M; Aria F; Bonini SA; Maccarinelli G; Gianoncelli A; Pina SD; Tambaro S; Memo M; Mastinu A
    Life Sci; 2019 May; 224():120-127. PubMed ID: 30910646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.